Advances in vaccine adjuvants for infectious diseases.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Current HIV Research

• Publication date

  2003-06-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1570162033485195PMID 15046255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

  2003cited by this paper
• Prevention of Disease Induced by a Partially Heterologous AIDS Virus in Rhesus Monkeys by Using an Adjuvanted Multicomponent Protein Vaccine

  2003cited by this paper
• Cross-Protective Immunity of Mice Induced by Oral Immunization with Pneumococcal Surface Adhesin A Encapsulated in Microspheres

  2002cited by this paper
• Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo.

  2002cited by this paper
• Analysis of Poly(D,L-Lactic-Co-Glycolic Acid) Nanosphere Uptake by Human Dendritic Cells and Macrophages In Vitro

  2002cited by this paper
• Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.

  2002cited by this paper
• Catching target receptors for drug and vaccine delivery using TOGA gene expression profiling.

  2002cited by this paper
• A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines.

  2002cited by this paper
• Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen.

  2002cited by this paper
• Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge.

  2002cited by this paper
• Detoxification of endotoxin by aluminum hydroxide adjuvant.

  2001cited by this paper
• The Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates Accessory Properties of Human Monocytes via an Interleukin-4-Dependent Mechanism

  2001cited by this paper
• Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

  2001cited by this paper
• Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

  2001cited by this paper
• Microparticles for intranasal immunization.

  2001cited by this paper
• Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines

  2001cited by this paper
• Tetanus Toxoid Loaded Nanoparticles from Sulfobutylated Poly(Vinyl Alcohol)-Graft-Poly(Lactide-co-Glycolide): Evaluation of Antibody Response After Oral and Nasal Application in Mice

  2001cited by this paper
• A Th1-Inducing Adjuvant, MPL®, Enhances Antibody Profiles in Experimental Animals Suggesting It Has the Potential to Improve the Efficacy of Allergy Vaccines

  2001cited by this paper
• Tissue distribution of radioactivity following intranasal administration of radioactive microspheres

  2001cited by this paper
• Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization

  2001cited by this paper
• A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.

  2001cited by this paper
• Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant.

  2001cited by this paper
• DNA Vaccination with the Human Immunodeficiency Virus Type 1 SF162ΔV2 Envelope Elicits Immune Responses That Offer Partial Protection from Simian/Human Immunodeficiency Virus Infection to CD8+ T-Cell-Depleted Rhesus Macaques

  2001cited by this paper
• Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.

  2001cited by this paper
• Oral vaccination in man using antigens in particles: current status.

  2001cited by this paper
• The Preparation, Characterization, and Evaluation of Cationic Microparticles for DNA Vaccine Delivery

  2001cited by this paper
• Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA

  2001cited by this paper
• Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity.

  2001cited by this paper
• Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.

  2001cited by this paper
• Cationic microparticles: A potent delivery system for DNA vaccines.

  2000cited by this paper
• In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.

  2000cited by this paper
• Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation.

  2000cited by this paper
• A Toll-like receptor recognizes bacterial DNA

  2000cited by this paper
• Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.

  2000cited by this paper
• Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells

  2000cited by this paper
• The ADP-Ribosylating CTA1-DD Adjuvant Enhances T Cell-Dependent and Independent Responses by Direct Action on B Cells Involving Anti-Apoptotic Bcl-2- and Germinal Center-Promoting Effects1

  2000cited by this paper
• Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

  2000cited by this paper
• Development of a preventive vaccine for Ebola virus infection in primates

  2000cited by this paper
• Formulation of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery.

  2000cited by this paper
• Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins.

  1999cited by this paper
• Genetically Detoxified Mutants of Heat-Labile Toxin from Escherichia coli Are Able To Act as Oral Adjuvants

  1999cited by this paper
• DNA vaccines--designer vaccines for the 21st century.

  1999cited by this paper
• Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.

  1999cited by this paper
• Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population

  1999cited by this paper
• Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo.

  1999cited by this paper
• Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells

  1999cited by this paper
• Intranasal Immunization with Pneumococcal Polysaccharide Conjugate Vaccines with Nontoxic Mutants of Escherichia coliHeat-Labile Enterotoxins as Adjuvants Protects Mice against Invasive Pneumococcal Infections

  1999cited by this paper
• PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization.

  1999cited by this paper
• MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.

  1999cited by this paper
• Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs.

  1999cited by this paper
• A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant.

  1999cited by this paper
• Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics.

  1999cited by this paper
• Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response.

  1999cited by this paper
• Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

  1999cited by this paper
• CpG motifs as immune adjuvants.

  1999cited by this paper
• Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses

  1998cited by this paper
• Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

  1998cited by this paper
• Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity

  1998cited by this paper
• A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

  1998cited by this paper
• Use of cellular and cytokine adjuvants in the immunotherapy of cancer

  1998cited by this paper
• Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice.

  1998cited by this paper
• Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

  1998cited by this paper
• Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo.

  1998cited by this paper
• Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses

  1998cited by this paper
• Improving protein therapeutics with sustained-release formulations

  1998cited by this paper
• Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.

  1998cited by this paper
• Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

  1998cited by this paper
• Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids.

  1998cited by this paper
• Optimism over vaccines administered via mucosal surfaces.

  1998cited by this paper
• Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

  1998cited by this paper
• Biologically erodable microspheres as potential oral drug delivery systems

  1997cited by this paper
• The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice.

  1997cited by this paper
• Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles.

  1997cited by this paper
• Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines.

  1997cited by this paper
• Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin

  1997cited by this paper
• Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.

  1997cited by this paper
• Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins

  1997cited by this paper
• Innate Immunity: The Virtues of a Nonclonal System of Recognition

  1997cited by this paper
• Characterization of Poly(glycolide-co-D,L-lactide)/Poly(D,L-lactide) Microspheres for Controlled Release of GM-CSF

  1997cited by this paper
• Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

  1997cited by this paper
• Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles.

  1997cited by this paper
• Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.

  1997cited by this paper
• Enhanced Oral Uptake of Tomato Lectin-Conjugated Nanoparticles in the Rat

  1997cited by this paper
• Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop

  1997cited by this paper
• HIV‐1‐specific cell‐mediated immune responses induced by DNA vaccination were enhanced by mannan‐coated liposomes and inhibited by anti‐interferon‐γ antibody

  1997cited by this paper
• Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine

  1997cited by this paper
• Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres

  1997cited by this paper
• Antigen localisation regulates immune responses in a dose‐ and time‐dependent fashion: a geographical view of immune reactivity

  1997cited by this paper
• Immunogenicity and protectivity of a new liposomal hepatitis A vaccine.

  1997cited by this paper
• Lectin-bearing Polymerized Liposomes as Potential Oral Vaccine Carriers

  1996cited by this paper
• Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

  1996cited by this paper
• Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection

  1996cited by this paper
• Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity.

  1996cited by this paper
• Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.

  1996cited by this paper
• The Instructive Role of Innate Immunity in the Acquired Immune Response

  1996cited by this paper
• MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice.

  1996cited by this paper
• Oral immunization with an anti–idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection

  1996cited by this paper
• MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates.

  1996cited by this paper
• The intestinal uptake of particles and the implications for drug and antigen delivery.

  1996cited by this paper
• Saponins as vaccine adjuvants.

  1996cited by this paper

• Epitope Analysis and Efficacy Evaluation of Phosphatase 2C (PP2C) DNA Vaccine Against Toxoplasma gondii Infection.

  2020cites this paper
• Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.

  2020cites this paper
• Endogenous and Exogenous Natural Adjuvants for Vaccine Development.

  2017cites this paper
• Facile fabrication of varisized calcium carbonate microspheres as vaccine adjuvants.

  2017cites this paper
• Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii

  2017cites this paper
• Development of nanostructures in the diagnosis of drug hypersensitivity reactions

  2016cites this paper
• Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands

  2014cites this paper
• A DNA vaccine encoding p39 and sp41 of Brucella melitensis induces protective immunity in BALB/c mice

  2014cites this paper
• The mycobacterial cord factor adjuvant analogue trehalose-6,6'-dibehenate (TDB) activates the Nlrp3 inflammasome.

  2013cites this paper
• Nanoparticles and microparticles of polymers and polysaccharides to administer fish vaccines.

  2013cites this paper
• An Empirical Approach towards the Efficient and Optimal Production of Influenza-Neutralizing Ovine Polyclonal Antibodies Demonstrates That the Novel Adjuvant CoVaccine HT™ Is Functionally Superior to Freund's Adjuvant

  2013cites this paper
• Nanotechnology in Vaccine Development

  2012cites this paper
• Targeted nanotherapy for induction of therapeutic immune responses.

  2012cites this paper
• PLGA and PLA particles as vaccine delivery systems for Atlantic salmon : a study on formulation and use with an emphasis on immune responses

  2012cites this paper
• STI vaccines: a review

  2012cites this paper
• Transgenesis, Paratransgenesis and Transmission Blocking Vaccines to Prevent Insect-Borne Diseases

  2012influential citation
• TDB) activates the Nlrp3 inflammasome

  2012cites this paper
• An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection.

  2012cites this paper
• LA class II transgenic mice develop a safe and long lasting immune response gainst StreptInCor , an anti-group A streptococcus vaccine candidate ilton

  2011cites this paper
• ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses.

  2011cites this paper
• Nanoparticles and modulation of immune responses

  2011cites this paper
• Bioinformatics for immunomics

  2010cites this paper
• Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein.

  2010cites this paper
• Porcine lactoferrin administration enhances peripheral lymphocyte proliferation and assists infectious bursal disease vaccination in native chickens.

  2010cites this paper
• Recombinant in vitro assembled hepatitis C virus core particles induce strong specific immunity enhanced by formulation with an oil-based adjuvant.

  2009cites this paper
• Vaccine adjuvants: current challenges and future approaches.

  2009cites this paper
• Biomimetic approaches to modulating the T cell immune response with nano- and micro- particles

  2009cites this paper
• In vitro and in vivo evaluation of novel biodegradable polymer adjuvants for vaccine delivery

  2009cites this paper
• Computational Vaccinology

  2009cites this paper
• Human Immunodeficiency Virus

  2009cites this paper
• Conjugation of protein antigen to microparticulate β-glucan from Saccharomyces cerevisiae: a new adjuvant for intradermal and oral immunizations

  2008cites this paper
• Design opportunities for actively targeted nanoparticle vaccines.

  2008cites this paper
• Proteomics integrated with Escherichia coli vector‐based vaccines and antigen microarrays reveals the immunogenicity of a surface sialidase‐like protein of Propionibacterium acnes

  2008cites this paper
• Promising particle-based vaccines in cancer therapy

  2008cites this paper
• A novel immunogenic spore coat-associated protein in Bacillus anthracis: characterization via proteomics approaches and a vector-based vaccine system.

  2008cites this paper
• A vaccine against atherosclerosis: myth or reality?

  2008cites this paper
• Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis.

  2007cites this paper
• Harnessing bioinformatics to discover new vaccines.

  2007cites this paper
• General Strategy for Decoration of Enveloped Viruses with Functionally Active Lipid-Modified Cytokines

  2007cites this paper
• AVALIAÇÃO DA RESPOSTA IMUNE A VACINAS DE ANTÍGENO PARTICULADO DE Leishmania sp E SUA ASSOCIAÇÃO COM VACINA DE DNA pCI-neo-p36(LACK) EM CAMUNDONGOS BALB/c DESAFIADOS COM Leishmania chagasi

  2007cites this paper
• PHARMACEUTICALLY ENGINEERED NANOPARTICLES FOR ENHANCING IMMUNE RESPONSES TO HIV-1 TAT AND GAG p24 PROTEINS

  2006cites this paper
• Heat Shock Proteins (HSP): Future Trends in Cancer Immunotherapy

  2006cites this paper
• Pathogen recognition and development of particulate vaccines: does size matter?

  2006cites this paper
• Bifidobacteria DNA induces murine macrophages activation in vitro.

  2005cites this paper
• Compositions immunomodulatrices, leurs methodes de preparation et utilisation

  2003cites this paper